NASDAQ:HOLX - Hologic Stock Price, Price Target & More

Get Started

$39.07 +0.35 (+0.90 %)

(As of 05/25/2018 11:01 AM ET)

Previous Close$38.92

Today's Range$38.80 - $39.15

52-Week Range$35.10 - $46.80

Volume17,436 shs

Average Volume2.57 million shs

Market Capitalization$10.60 billion

P/E Ratio19.15

Dividend YieldN/A

Beta0.87

About Hologic (NASDAQ:HOLX)

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health. It offers Aptima family of assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assay technologies, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test products. It also provides breast imaging and related products, and accessories comprising digital and film-based mammography systems; computer-aided detection for mammography; minimally invasive breast biopsy devices; breast biopsy site markers; and breast biopsy guidance systems. In addition, it offers Dimensions platform, a mammography gantry for 2D and tomosynthesis image acquisition and display; C-View and Intelligent 2D, a software product that provides 2D images; Selenia digital mammography platform; and SecurView Workstation. Further, it provides SculpSure, MonaLisa Touch, Vectus diode, and Cellulaze laser devices; PicoSure and Icon aesthetic systems; MedLite, RevLite, Cynergy, Elite, and SmartLipo products; and system components. Additionally, it offers NovaSure system to treat women suffering from abnormal uterine bleeding; MyoSure system for the hysteroscopic removal of fibroids; discovery and horizon X-ray bone densitometers that assess the bone density of fracture sites; and mini C-arm imaging systems to perform minimally invasive surgical procedures on a patient's extremities, such as the hand, wrist, knee, foot, and ankle. The company sells its products through direct sales and service forces, and a network of independent distributors and sales representatives. Hologic, Inc. was founded in 1985 and is headquartered in Marlborough, Massachusetts.

Receive HOLX News and Ratings via Email

Sign-up to receive the latest news and ratings for HOLX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry X-ray apparatus & tubes

Sub-IndustryHealth Care Equipment

SectorMedical

SymbolNASDAQ:HOLX

CUSIP43644010

Webwww.hologic.com

Phone508-263-2900

Debt

Debt-to-Equity Ratio1.13

Current Ratio1.26

Quick Ratio0.98

Price-To-Earnings

Trailing P/E Ratio19.15

Forward P/E Ratio17.44

P/E Growth1.83

Sales & Book Value

Annual Sales$3.06 billion

Price / Sales3.49

Cash Flow$3.6893 per share

Price / Cash10.59

Book Value$8.96 per share

Price / Book4.36

Profitability

EPS (Most Recent Fiscal Year)$2.03

Net Income$755.50 million

Net Margins-4.15%

Return on Equity20.86%

Return on Assets7.51%

Miscellaneous

Employees6,233

Outstanding Shares273,010,000

Hologic (NASDAQ:HOLX) Frequently Asked Questions

What is Hologic's stock symbol?

Hologic trades on the NASDAQ under the ticker symbol "HOLX."

How were Hologic's earnings last quarter?

Hologic, Inc. (NASDAQ:HOLX) announced its quarterly earnings data on Wednesday, May, 2nd. The medical equipment provider reported $0.53 earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of $0.53. The medical equipment provider earned $789.30 million during the quarter, compared to analysts' expectations of $781.23 million. Hologic had a negative net margin of 4.15% and a positive return on equity of 20.86%. The firm's revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.50 EPS. View Hologic's Earnings History.

What guidance has Hologic issued on next quarter's earnings?

Hologic updated its FY18 earnings guidance on Wednesday, May, 2nd. The company provided EPS guidance of $2.22-2.27 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.26. The company issued revenue guidance of $3.18-3.21 billion, compared to the consensus revenue estimate of $3.25 billion.Hologic also updated its Q3 guidance to $0.55-0.57 EPS.

What price target have analysts set for HOLX?

14 analysts have issued 12 month target prices for Hologic's stock. Their forecasts range from $39.00 to $52.00. On average, they expect Hologic's share price to reach $45.00 in the next twelve months. View Analyst Ratings for Hologic.

What are Wall Street analysts saying about Hologic stock?

Here are some recent quotes from research analysts about Hologic stock:

1. BTIG Research analysts commented, "in the New Year; Maintain Buy, $17 PT Our thesis is unchanged as SPNE put up solid results in 1Q18. Recall that SPNE has been transitioning the US spinal hardware business from legacy products to newer products that should (and are) growing at a faster pace, namely Mariner and Shoreline. While it has taken a few quarters, SPNE now has ~45% (up from ~24% in 1Q17) of its US spinal implant revenue coming from newer products. Combined with a growing exclusive distributor base, results came in slightly above expectations at $33.2M (+4.0%) relative to BTIG/Consensus of $32.5M/$32.7M respectively. In addition, orthobiologics continues to grow in the MSD from the strength of the portfolio, +5.2% WW, +4.9% US. SPNE is launching multiple products in both categories through FY18 (including a lateral system, Regatta, in 3Q18) while also developing instrumentation that works with navigation access. Collectively, the business continues its positive progression, the portfolio continues to build, and growth should increase to the MSD to HSD in 2H18. While macro spine dynamics remain soft, SPNE is a share taker (even if it is at a smaller scale than others). We maintain our Buy rating and $17 PT." (5/6/2018)
2. Needham & Company LLC analysts commented, "FDA’s latest monthly Mammography Quality Standards Act (MQSA) statistics were published on 5/1/18. The number of digital breast tomosynthesis (DBT) units increased by 199 during April which represents a 165.3% Y/ Y increase. DBT unit penetration increased to 31.8% from 31.1% last month and facility penetration increased to 49.6% from 48.1% last month. More importantly, DBT units placements are up 29.4% year-to-date (YTD) in 2018 vs. 2017. Assuming that HOLX is at least holding mammography market share, we believe its Breast Health business could accelerate some in 2018 given the strong YTD US mammography placements. We note that HOLX’s 3D mammography sales are less than 13% of its total sales." (5/1/2018)
3. According to Zacks Investment Research, "Over the past three months, Hologic has been underperforming its industry. The company's blood screening divestiture continues to impede growth. Foreign currency headwinds and a competitive landscape also continue to pose challenges for the company. On a positive note, Hologic has been witnessing strength in the Molecular Diagnostics. Moreover, growth across all geographical regions buoys optimism. Buoyed on differentiated products, Breast Health has been performing well. We are upbeat about the recent CE Mark approval for Brevera breast biopsy system. Also, the PMA approval for the Aptima HBV Quant Assay for quantitation of hepatitis B viral load on the fully automated Panther system buoys optimism. Hologic’s strong cash position is encouraging." (4/30/2018)

Who are some of Hologic's key competitors?

Some companies that are related to Hologic include Boston Scientific (BSX), Zoetis (ZTS), Beximco Pharmaceuticals (BXP), Humana (HUM), Vertex Pharmaceuticals (VRTX), Illumina (ILMN), Baxter International (BAX), HCA Healthcare (HCA), Takeda Pharmaceutical (TKPYY), Regeneron (REGN), Fresenius Medical Care (FMS), Astellas Pharma (ALPMY), Essilor International (ESLOY), McKesson (MCK) and Actelion (ALIOF).

Who are Hologic's key executives?

Hologic's management team includes the folowing people:

Mr. Stephen P. MacMillan, Chairman, CEO & Pres (Age 54)
Mr. Robert W. McMahon, Chief Financial Officer (Age 49)
Mr. John M. Griffin, Gen. Counsel (Age 57)
Mr. Peter J. Valenti III, Division Pres of Breast & Skeletal Health Solutions (Age 55)
Mr. Eric B. Compton, Consultant (Age 53)

Has Hologic been receiving favorable news coverage?

News headlines about HOLX stock have been trending very positive on Friday, according to Accern Sentiment. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Hologic earned a coverage optimism score of 0.65 on Accern's scale. They also gave media coverage about the medical equipment provider an impact score of 46.69 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are Hologic's major shareholders?

Hologic's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.33%), Victory Capital Management Inc. (2.00%), Wells Fargo & Company MN (1.76%), Northern Trust Corp (1.27%), Dimensional Fund Advisors LP (0.84%) and Guggenheim Capital LLC (0.64%). Company insiders that own Hologic stock include Allison P Bebo, Charles J Dockendorff, Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy, Namal Nawana, Nancy Leaming, Peter J Valenti III and Sally Crawford. View Institutional Ownership Trends for Hologic.

Which major investors are selling Hologic stock?

HOLX stock was sold by a variety of institutional investors in the last quarter, including Mackay Shields LLC, Allianz Asset Management GmbH, Allianz Asset Management GmbH, BlackRock Inc., Wells Fargo & Company MN, The Manufacturers Life Insurance Company , JPMorgan Chase & Co. and Thrivent Financial for Lutherans. Company insiders that have sold Hologic company stock in the last year include Allison P Bebo, Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy and Peter J Valenti III. View Insider Buying and Selling for Hologic.

Which major investors are buying Hologic stock?

HOLX stock was purchased by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Natixis, Dimensional Fund Advisors LP, Stevens Capital Management LP, NS Partners Ltd, BNP Paribas Arbitrage SA, BB&T Securities LLC and Verition Fund Management LLC. Company insiders that have bought Hologic stock in the last two years include Charles J Dockendorff and Namal Nawana. View Insider Buying and Selling for Hologic.

How do I buy shares of Hologic?

Shares of HOLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Hologic's stock price today?

One share of HOLX stock can currently be purchased for approximately $39.11.

How big of a company is Hologic?

Hologic has a market capitalization of $10.60 billion and generates $3.06 billion in revenue each year. The medical equipment provider earns $755.50 million in net income (profit) each year or $2.03 on an earnings per share basis. Hologic employs 6,233 workers across the globe.

How can I contact Hologic?

Hologic's mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-263-2900 or via email at [email protected]

MarketBeat Community Rating for Hologic (HOLX)

Community Ranking:		3.0 out of 5 ( )
Outperform Votes:		600 (Vote Outperform)
Underperform Votes:		411 (Vote Underperform)
Total Votes:		1,011

MarketBeat's community ratings are surveys of what our community members think about Hologic and other stocks. Vote "Outperform" if you believe HOLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HOLX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Hologic (NASDAQ:HOLX) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

14 Wall Street analysts have issued ratings and price targets for Hologic in the last 12 months. Their average twelve-month price target is $45.00, suggesting that the stock has a possible upside of 15.18%. The high price target for HOLX is $52.00 and the low price target for HOLX is $39.00. There are currently 5 hold ratings and 9 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.64	2.69	2.79	2.69
Ratings Breakdown:	0 Sell Rating(s) 5 Hold Rating(s) 9 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 4 Hold Rating(s) 9 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 4 Hold Rating(s) 9 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 4 Hold Rating(s) 9 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$45.00	$47.5385	$48.3571	$47.5385
Price Target Upside:	15.18% upside	22.93% upside	28.10% upside	21.55% upside

Hologic (NASDAQ:HOLX) Consensus Price Target History

Price Target History for Hologic (NASDAQ:HOLX)

Hologic (NASDAQ:HOLX) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/6/2018	BTIG Research	Reiterated Rating	Buy	$44.00	Medium
5/3/2018	Barclays	Lower Price Target	Overweight ➝ Overweight	$54.00 ➝ $50.00	High
5/3/2018	Deutsche Bank	Lower Price Target	Hold ➝ Hold	$44.00 ➝ $42.00	High
5/3/2018	Stifel Nicolaus	Lower Price Target	Hold ➝ Hold	$42.00 ➝ $40.00	High
5/3/2018	Leerink Swann	Downgrade	Outperform ➝ Market Perform	$48.00 ➝ $41.00	High
5/3/2018	Canaccord Genuity	Downgrade	Buy ➝ Hold	$48.00 ➝ $39.00	High
5/1/2018	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $43.00	Low
4/17/2018	Goldman Sachs Group	Set Price Target	Buy	$43.00	Low
2/9/2018	Royal Bank of Canada	Reiterated Rating	Hold	$44.00	High
1/4/2018	Bank of America	Upgrade	Neutral ➝ Buy	$50.00	Low
1/3/2018	Evercore ISI	Initiated Coverage	Outperform ➝ Outperform	$50.00	Medium
12/20/2017	Cowen	Upgrade	Buy	$52.00	Low
11/9/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$48.00	N/A
10/10/2017	Jefferies Group	Reiterated Rating	Buy	$49.00 ➝ $44.00	N/A
7/28/2016	Morgan Stanley	Boost Price Target	Equal Weight	$38.00 ➝ $40.00	N/A
7/17/2016	UBS	Reiterated Rating	Buy	$45.00	N/A

(Data available from 5/25/2016 forward)

Hologic (NASDAQ:HOLX) Earnings History and Estimates Chart

Earnings by Quarter for Hologic (NASDAQ:HOLX)

Hologic (NASDAQ:HOLX) Earnings Estimates

2018 EPS Consensus Estimate: $2.19
2019 EPS Consensus Estimate: $2.52

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	3	$0.49	$0.52	$0.50
Q2 2018	3	$0.51	$0.52	$0.52
Q3 2018	4	$0.55	$0.57	$0.57
Q4 2018	4	$0.60	$0.61	$0.61
Q1 2019	2	$0.61	$0.63	$0.62
Q2 2019	1	$0.60	$0.60	$0.60
Q3 2019	2	$0.61	$0.65	$0.63
Q4 2019	2	$0.63	$0.70	$0.67

Hologic (NASDAQ HOLX) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/2/2018	Q2 2018	$0.53	$0.53	$781.23 million	$789.30 million	View	N/A
2/8/2018	Q1 2018	$0.50	$0.55	$785.80 million	$791.10 million	View	Listen
11/8/2017	Q4 2017	$0.49	$0.50	$792.54 million	$802.90 million	View	N/A
8/2/2017	Q3 2017	$0.49	$0.50	$799.70 million	$806.10 million	View	Listen
5/10/2017	Q2 17	$0.46	$0.50	$685.24 million	$715.40 million	View	N/A
2/1/2017	Q117	$0.51	$0.52	$725.01 million	$734.40 million	View	Listen
11/2/2016	Q416	$0.50	$0.52	$721.52 million	$726.80 million	View	N/A
7/27/2016	Q316	$0.48	$0.51	$703.66 million	$717.40 million	View	Listen
4/27/2016	Q216	$0.46	$0.47	$686.82 million	$693.30 million	View	Listen
1/27/2016	Q116	$0.42	$0.46	$688.68 million	$695.20 million	View	Listen
11/4/2015	Q415	$0.42	$0.43	$691.94 million	$702.80 million	View	Listen
7/29/2015	Q315	$0.39	$0.43	$653.85 million	$693.90 million	View	Listen
4/29/2015	Q215	$0.39	$0.41	$646.49 million	$655.50 million	View	N/A
1/28/2015	Q115	$0.36	$0.39	$630.79 million	$652.80 million	View	Listen
11/5/2014	Q414	$0.37	$0.43	$636.20 million	$660.60 million	View	Listen
7/30/2014	Q314	$0.34	$0.37	$621.89 million	$632.60 million	View	Listen
4/30/2014	Q214	$0.33	$0.37	$609.35 million	$625.00 million	View	Listen
2/3/2014	Q114	$0.31	$0.34	$609.65 million	$612.40 million	View	Listen
11/11/2013	Q413	$0.37	$0.39	$624.40 million	$622.10 million	View	Listen
8/5/2013	Q3 2013	$0.37	$0.38	$627.05 million	$626.10 million	View	Listen
5/6/2013	Q2 2013	$0.34	$0.35	$639.53 million	$619.10 million	View	Listen
2/4/2013	Q1 2013	$0.37	$0.38	$646.52 million	$644.60 million	View	Listen
11/12/2012	Q412	$0.36	$0.37	$581.12 million	$600.20 million	View	N/A
7/30/2012		$0.34	$0.35			View	N/A
4/30/2012		$0.33	$0.33			View	N/A
1/30/2012		$0.32	$0.34			View	N/A
11/7/2011		$0.33	$0.34			View	N/A
8/1/2011		$0.32	$0.32			View	N/A
5/2/2011		$0.28	$0.30			View	N/A
1/31/2011		$0.28	$0.30			View	N/A
11/8/2010	Q4 2010	$0.30	$0.30			View	N/A
8/2/2010	Q3 2010	$0.29	$0.30			View	N/A
5/3/2010	Q2 2010	$0.29	$0.29			View	N/A
2/1/2010	Q1 2010	$0.26	$0.29			View	N/A
11/9/2009	Q4 2009	$0.26	$0.28			View	N/A
8/3/2009	Q3 2009	$0.26	$0.29			View	N/A
5/4/2009	Q2 2009	$0.27	$0.29			View	N/A
2/2/2009	Q1 2009	$0.30	$0.31			View	N/A
11/11/2008	Q4 2008	$0.30	$0.30			View	N/A
7/30/2008	Q3 2008	$0.29	$0.33			View	N/A
5/1/2008	Q2 2008	$0.28	$0.29			View	N/A
1/31/2008	Q1 2008	$0.23	$0.25			View	N/A

(Earnings results data provided by Zacks Investment Research)

Hologic (NASDAQ:HOLX) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Hologic (NASDAQ HOLX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.79%
Institutional Ownership Percentage: 99.80%

Insider Trading History for Hologic (NASDAQ:HOLX)

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Hologic (NASDAQ HOLX) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/2/2018	Karleen Marie Oberton	VP	Sell	12,196	$40.00	$487,840.00	13,825
3/16/2018	Allison P. Bebo	SVP	Sell	7,000	$38.75	$271,250.00
3/15/2018	Charles J Dockendorff	Director	Buy	13,000	$38.80	$504,400.00
2/13/2018	Namal Nawana	Director	Buy	6,600	$37.88	$250,008.00	6,954
11/20/2017	Karleen Marie Oberton	VP	Sell	1,023	$39.84	$40,756.32
11/13/2017	Elaine Ullian	Director	Sell	9,282	$40.50	$375,921.00
11/8/2017	Karleen Marie Oberton	VP	Sell	1,256	$39.29	$49,348.24	9,406
11/6/2017	Karleen Marie Oberton	VP	Sell	538	$39.40	$21,197.20	8,343
10/10/2017	Lawrence M Levy	Director	Sell	9,596	$36.81	$353,228.76
10/9/2017	Lawrence M Levy	Director	Sell	7,138	$37.38	$266,818.44
9/7/2017	Lawrence M. Levy	Director	Sell	7,139	$39.04	$278,706.56
8/3/2017	Elaine Ullian	Director	Sell	6,902	$40.12	$276,908.24	23,810
7/17/2017	Karleen Marie Oberton	VP	Sell	4,704	$45.19	$212,573.76
7/3/2017	Elaine Ullian	Director	Sell	8,849	$45.28	$400,682.72	23,810
6/7/2017	Lawrence M Levy	Director	Sell	2,960	$44.54	$131,838.40	45,634
6/2/2017	Elaine Ullian	Director	Sell	8,938	$43.99	$393,182.62	23,810
5/30/2017	Peter J Valenti III	Insider	Sell	10,005	$43.44	$434,617.20	20,994
5/24/2017	Lawrence M Levy	Director	Sell	9,193	$42.93	$394,655.49	46,206
5/17/2017	Lawrence M Levy	Director	Sell	9,076	$42.80	$388,452.80	43,165
5/10/2017	Lawrence M Levy	Director	Sell	9,837	$45.34	$446,009.58	40,577
5/3/2017	Lawrence M Levy	Director	Sell	10,203	$45.00	$459,135.00	38,832
4/26/2017	Lawrence M Levy	Director	Sell	10,374	$44.46	$461,228.04	37,377
4/24/2017	Sally Crawford	Director	Sell	16,969	$44.00	$746,636.00	157,305
4/19/2017	Lawrence M Levy	Director	Sell	10,836	$42.49	$460,421.64	25,839
4/12/2017	Lawrence M Levy	Director	Sell	10,757	$42.45	$456,634.65	24,596
4/3/2017	Elaine Ullian	Director	Sell	9,104	$42.40	$386,009.60	23,810
3/8/2017	Sally Crawford	Director	Sell	17,396	$42.00	$730,632.00	152,305
2/3/2017	Elaine Ullian	Director	Sell	9,423	$39.54	$372,585.42	36,798
11/21/2016	Karleen Marie Oberton	VP	Sell	3,023	$38.32	$115,841.36	13,260
11/15/2016	Karleen Marie Oberton	VP	Sell	1,211	$36.55	$44,262.05	10,859
11/8/2016	Karleen Marie Oberton	VP	Sell	984	$38.57	$37,952.88	9,065
11/7/2016	Karleen Marie Oberton	VP	Sell	522	$38.53	$20,112.66	9,839
10/10/2016	Elaine Ullian	Director	Sell	18,236	$39.88	$727,251.68	42,898
10/10/2016	Karleen Marie Oberton	VP	Sell	31,470	$40.00	$1,258,800.00	17,005
7/21/2016	Nancy Leaming	Director	Sell	8,179	$37.00	$302,623.00	67,140
7/11/2016	Nancy Leaming	Director	Sell	6,221	$36.04	$224,204.84	55,053
6/1/2016	Lawrence M Levy	Director	Sell	17,794	$34.41	$612,291.54	23,257
5/27/2016	Peter J Valenti III	Insider	Sell	10,022	$33.83	$339,044.26	9,023
5/26/2016	Elaine Ullian	Director	Sell	6,896	$33.85	$233,429.60	31,157
5/26/2016	Karleen Marie Oberton	VP	Sell	4,228	$33.85	$143,117.80	8,819
2/24/2016	David R Lavance Jr	Director	Sell	11,621	$34.50	$400,924.50	20,983
11/10/2015	Lawrence M. Levy	Director	Sell	20,000	$40.70	$814,000.00	3,914
9/21/2015	Lawrence M. Levy	Director	Sell	5,000	$42.02	$210,100.00	3,914
9/8/2015	Wayne Wilson	Director	Sell	100,000	$39.00	$3,900,000.00	39,215
8/28/2015	Wayne Wilson	Director	Sell	11,146	$39.70	$442,496.20	39,215
8/26/2015	Wayne Wilson	Director	Sell	25,080	$38.61	$968,338.80	39,215
8/14/2015	Wayne Wilson	Director	Sell	13,257	$42.20	$559,445.40
6/3/2015	Lawrence M Levy	Director	Sell	10,000	$36.45	$364,500.00
5/22/2015	Lawrence M Levy	Director	Sell	5,000	$35.05	$175,250.00
5/4/2015	Lawrence M Levy	Director	Sell	10,000	$34.36	$343,600.00
3/6/2015	David R Lavance Jr	Director	Sell	12,000	$32.12	$385,440.00
2/13/2015	David R Lavance Jr	Director	Sell	8,000	$30.32	$242,560.00
1/29/2015	Karleen Marie Oberton	VP	Sell	18,997	$30.00	$569,910.00
11/11/2014	Karleen Marie Oberton	VP	Sell	2,609	$26.30	$68,616.70
11/3/2014	Karleen Marie Oberton	VP	Sell	12,507	$26.83	$335,562.81
10/31/2014	Roger D Mills	SVP	Sell	14,506	$26.00	$377,156.00
9/9/2014	Elaine Ullian	Director	Buy	7,900	$25.36	$200,344.00
5/9/2014	Rohan Hastie	SVP	Sell	6,037	$24.36	$147,061.32	1,500
5/8/2014	Glenn Muir	CFO	Sell	50,000	$24.26	$1,213,000.00	815,306
5/6/2014	Glenn Muir	CFO	Sell	196,000	$23.29	$4,564,840.00	815,306
5/6/2014	Lawrence Levy	Director	Sell	5,052	$23.58	$119,126.16
5/6/2014	Robert Lavallee	CAO	Sell	22,796	$23.58	$537,529.68	11,341
3/14/2014	David Lavance, Jr.	Director	Sell	5,500	$21.49	$118,195.00	122
3/14/2014	Glenn Muir	CFO	Sell	160,000	$21.51	$3,441,600.00	815,306
3/7/2014	Mark Casey	CAO	Sell	3,251	$22.53	$73,245.03	14,470
2/11/2014	Stephen Macmillan	CEO	Buy	38,600	$21.58	$832,988.00	237,500
2/7/2014	Stephen Macmillan	CEO	Buy	198,900	$20.78	$4,133,142.00	198,900
12/13/2013	Robert Lavallee	CAO	Sell	15,677	$21.70	$340,190.90	11,341
10/30/2013	Glenn P Muir	CFO	Sell	140,000	$22.32	$3,124,800.00
10/15/2013	Glenn P Muir	CFO	Sell	28,000	$22.12	$619,360.00
9/16/2013	Glenn Muir	CFO	Sell	28,000	$20.45	$572,600.00	825,891
9/13/2013	Robert Lavallee	CAO	Sell	2,500	$20.33	$50,825.00	19,090
8/20/2013	David Brady	SVP	Sell	42,328	$22.80	$965,078.40	27,749
8/15/2013	Glenn Muir	CFO	Sell	28,000	$22.49	$629,720.00	825,891
8/8/2013	Lawrence Levy	Director	Sell	5,000	$22.50	$112,500.00	5,052
8/8/2013	Mark Casey	CAO	Sell	14,804	$22.57	$334,126.28	20,632
7/19/2013	Robert H Lavallee	CAO	Sell	11,254	$20.89	$235,096.06
7/15/2013	Glenn P Muir	CFO	Sell	28,000	$19.78	$553,840.00
7/1/2013	Robert Cascella	CEO	Sell	20,000	$19.55	$391,000.00
6/17/2013	Glenn P Muir	CFO	Sell	28,000	$21.42	$599,760.00
6/3/2013	Robert Cascella	CEO	Sell	20,000	$20.71	$414,200.00
2/25/2013	Lawrence M Levy	Director	Sell	5,000	$22.00	$110,000.00
9/5/2012	Glenn P Muir	CFO	Sell	68,750	$19.96	$1,372,250.00
8/8/2012	Glenn P Muir	CFO	Sell	68,750	$19.69	$1,353,687.50

(Data available from 1/1/2013 forward)

Hologic (NASDAQ HOLX) News Headlines

Source:

Date	Headline
	$800.84 Million in Sales Expected for Hologic, Inc. (HOLX) This Quarter www.americanbankingnews.com - May 25 at 5:59 AM
	$0.56 EPS Expected for Hologic, Inc. (HOLX) This Quarter www.americanbankingnews.com - May 23 at 1:14 AM
	Hologic, Inc. (HOLX) Receives Average Rating of "Hold" from Analysts www.americanbankingnews.com - May 21 at 7:52 AM
	See what the IHS Markit Score report has to say about Hologic Inc. finance.yahoo.com - May 9 at 5:05 PM
	Hologic (HOLX) to Post Q4 2018 Earnings of $0.60 Per Share, Leerink Swann Forecasts www.americanbankingnews.com - May 7 at 4:20 AM
	Jefferies Group Weighs in on Hologic's FY2018 Earnings (HOLX) www.americanbankingnews.com - May 7 at 3:58 AM
	Hologic (HOLX) Expected to Earn Q3 2018 Earnings of $0.55 Per Share www.americanbankingnews.com - May 7 at 3:10 AM
	BTIG Research Reiterates "Buy" Rating for Hologic (HOLX) www.americanbankingnews.com - May 6 at 10:34 AM
	$0.57 EPS Expected for Hologic (HOLX) This Quarter www.americanbankingnews.com - May 5 at 3:11 PM
	Hologic (HOLX) Cut to C- at TheStreet www.americanbankingnews.com - May 4 at 11:27 PM
	Karleen Marie Oberton Sells 12,196 Shares of Hologic (HOLX) Stock www.americanbankingnews.com - May 4 at 7:52 PM
	US STOCKS ON THE MOVE-Cardinal Health, Tesla, AIG, Spotify, Caterpillar, Hologic, Kellogg www.nasdaq.com - May 4 at 8:47 AM
	William Blair Analysts Decrease Earnings Estimates for Hologic (HOLX) www.americanbankingnews.com - May 4 at 8:41 AM
	Jefferies Group Equities Analysts Increase Earnings Estimates for Hologic (HOLX) www.americanbankingnews.com - May 4 at 8:37 AM
	Research Analysts Offer Predictions for Hologic's Q3 2018 Earnings (HOLX) www.americanbankingnews.com - May 4 at 7:42 AM
	Critical Review: Check Cap (CHEK) & Hologic (HOLX) www.americanbankingnews.com - May 4 at 1:20 AM
	Hologic (HOLX) PT Lowered to $50.00 at Barclays www.americanbankingnews.com - May 4 at 12:17 AM
	Hologic (HOLX) Downgraded to "Sell" at ValuEngine www.americanbankingnews.com - May 3 at 11:10 PM
	Hologic (HOLX) Price Target Cut to $42.00 www.americanbankingnews.com - May 3 at 11:02 PM
	Stifel Nicolaus Cuts Hologic (HOLX) Price Target to $40.00 www.americanbankingnews.com - May 3 at 8:35 PM
	Hologic (HOLX) Releases Quarterly Earnings Results, Meets Estimates www.americanbankingnews.com - May 3 at 5:26 PM
	Top Analyst Upgrades and Downgrades: Andeavor, Discovery, Estee Lauder, Esperion Therapeutics, Hologic, Nvidia ... 247wallst.com - May 3 at 4:57 PM
	Hologic's (HOLX) Q2 Earnings Meet Estimates, Revenues Top www.nasdaq.com - May 3 at 4:57 PM
	Hologic (HOLX) Downgraded to Hold at Canaccord Genuity www.americanbankingnews.com - May 3 at 4:31 PM
	Hologic (HOLX) Cut to "Market Perform" at Leerink Swann www.americanbankingnews.com - May 3 at 4:31 PM
	Hologic (HOLX) Reports In-Line Q2 EPS; Lowers Rev Guidance, Maintains EPS www.streetinsider.com - May 3 at 8:45 AM
	BRIEF-Hologic Receives Health Canada Authorization To Market Sculpsure Laser www.reuters.com - May 3 at 8:45 AM
	Hologic (HOLX) Q2 2018 Results - Earnings Call Transcript seekingalpha.com - May 3 at 8:45 AM
	Edited Transcript of HOLX earnings conference call or presentation 2-May-18 8:30pm GMT finance.yahoo.com - May 3 at 8:44 AM
	Hologic Receives Health Canada Authorization to Market SculpSure® Laser for Non-Invasive Body Contouring (Lipolysis) of the Back, Inner and Outer Thighs, and Under the Chin finance.yahoo.com - May 3 at 8:44 AM
	Hologic (HOLX) Updates Q3 Earnings Guidance www.americanbankingnews.com - May 2 at 7:33 PM
	Hologic (HOLX) Updates FY18 Earnings Guidance www.americanbankingnews.com - May 2 at 7:32 PM
	BRIEF-Hologic Q2 GAAP Loss Per Share $2.46 www.reuters.com - May 2 at 5:08 PM
	Hologic Q2 18 Earnings Conference Call At 4:30 PM ET www.nasdaq.com - May 2 at 5:08 PM
	Hologic Announces Financial Results for Second Quarter of Fiscal 2018 finance.yahoo.com - May 2 at 5:08 PM
	Hologic: Fiscal 2Q Earnings Snapshot finance.yahoo.com - May 2 at 5:08 PM
	Hologic (HOLX) Receives "Buy" Rating from Needham & Company LLC www.americanbankingnews.com - May 1 at 4:18 PM
	Breast Cancer Screening Tests 2018: Global Market Growth, Trends, and Forecasts to 2023 - ResearchAndMarkets.com www.businesswire.com - May 1 at 8:53 AM
	Hologic (HOLX) Scheduled to Post Earnings on Tuesday www.americanbankingnews.com - May 1 at 2:44 AM
	Hologic (HOLX) Stock Rating Lowered by Zacks Investment Research www.americanbankingnews.com - April 30 at 11:41 AM
	Hologic (HOLX) Rating Increased to Hold at BidaskClub www.americanbankingnews.com - April 27 at 12:13 PM
	Leading Women's Health Company Hologic Features Its Innovative Suite of Products at 2018 American College of ... www.prnewswire.com - April 27 at 9:10 AM
	Leading Women's Health Company Hologic Features Its Innovative Suite of Products at 2018 American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting finance.yahoo.com - April 27 at 9:10 AM
	Minerva Surgical Requests Immediate Retraction of Misleading Int'l Journal of Women's Health Publication that Compares NovaSure to Minerva®, Sponsored by Hologic www.prnewswire.com - April 26 at 8:01 PM
	Global Virtual Reality (VR) in Healthcare Market 2015-2018 & 2023 Featuring Brainlab, Medtronic, Hologic, GE ... www.prnewswire.com - April 26 at 4:56 PM
	Check Cap (CHEK) and Hologic (HOLX) Critical Comparison www.americanbankingnews.com - April 26 at 9:38 AM
	Hologic (HOLX) Given Consensus Recommendation of "Buy" by Brokerages www.americanbankingnews.com - April 26 at 8:52 AM
	Contrasting Check Cap (CHEK) and Hologic (HOLX) www.americanbankingnews.com - April 25 at 9:26 PM
	BRIEF-FDA Approval Of Thinprep Integrated Imager Expands Automated Imaging For Pap Testing To More Labs www.reuters.com - April 25 at 8:48 AM
	Hologic (HOLX) Announces FDA Approval of ThinPrep www.streetinsider.com - April 25 at 8:48 AM

Hologic (NASDAQ:HOLX) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Hologic (NASDAQ:HOLX) Income Statement, Balance Sheet and Cash Flow Statement

Hologic (NASDAQ HOLX) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff